MLM has experience employing animal-based cell lines to evaluate emerging nutritional innovations via customizable biomarkers such as those described below. Particularly, animal gastrointestinal, immune or other cell lines can help provide insights into general metabolic or inflammatory response to foods or supplements. This in turn can help screen potential products or additives for greater efficiency.  Additionally, we have the capabilities to establish custom cell-based assays for many different therapeutic areas (e.g. gut inflammation, respiratory disease, dermal inflammation) which can provide additional support for therapeutic claims.
Read more

MLM offers animal sample testing of a broad range of matrices and customizable protein markers.  We can utilize Luminex or MSD platforms for large metabolic or inflammatory biomarker screening, as well as individual ELISA or enzyme-based assessments. Currently, we are developing assays for flow cytometry testing for differentiating immune cell populations within companion animal samples. 

Genomic markers may be evaluated using qPCR assessment allowing us to monitor changes in response to therapy or diet. MLM can further use mRNA expression to assess disease onset, analyze immune function, track therapeutic efficacy. Additionally, we can selectively monitor gut bacterial population in response to diet or inclusion of probiotics in food.

Animal tissue pathology may be assessed histologically using standard stains such as hematoxylin and eosin (HE) to evaluate general inflammation/immune cell infiltration or Masson’s Trichrome (MT) to look at collagen/fibrosis. We can also assess more specific targets via immunohistochemistry (IHC) or immunofluorescence (IF). We can additionally utilize in vitro hybridization (ISH) to look at genomic markers.
Read more

Coming Soon